Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 18/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.47 |
| ▸ | HTR2A | P28223 | 8/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | RHEB | Q15382 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7877568 | 0.92 | SLC6A4 (0.39) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL7880766 | 0.92 | RHEB (0.40) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL7873843 | 0.87 | RHEB (0.34) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL7880007 | 0.87 | RHEB (0.42) | RHEB | |
| SCHEMBL7878193 | 0.86 | SLC6A4 (0.41) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL7884286 | 0.86 | MEN1 (0.38) | KCNH2RHEB | |
| Hydrochloric Acid SCHEMBL7879992 | 0.86 | RHEB (0.41) | RHEB | |
| SCHEMBL7879705 | 0.85 | MEN1 (0.40) | KCNH2RHEB | |
| SCHEMBL7879889 | 0.84 | RHEB (0.50) | RHEB | |
| SCHEMBL7881957 | 0.84 | MEN1 (0.48) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6248772-B1 | HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| US-6169107-B1 | USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS | SUMITOMO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-0708091-A2 | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |